SOURCES SOUGHT
B -- Study on Influenza Virus (H5N1/H1N1) Infected Ferrets
- Notice Date
- 5/6/2013
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 3900 NCTR Road, HFT-320, Bldg 50 | Rm 421, Jefferson, Arkansas, 72079, United States
- ZIP Code
- 72079
- Solicitation Number
- FDA-SS-1115918
- Archive Date
- 6/4/2013
- Point of Contact
- Christopher R. McGucken, Phone: 3018277161
- E-Mail Address
-
christopher.mcgucken@fda.hhs.gov
(christopher.mcgucken@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- [Please note that this posting is for market research only, and is not a request for proposal or solicitation]. The Food and Drug Administration (FDA) of the U.S. Department of Health and Human services (DHHS) is conducting a market survey to seek potential sources from qualified small business firms under North American Industry Classification (NAICS) Code 541380 (Testing Laboratories). Project Title: Study on Influenza Virus (H5N1/H1N1)Infected Ferrets This study deals with measuring the cross-neutralizing ability of neutralized antibody in plasma. Based on published reports, plasma from patients can neutralize influenza. The FDA plans to verify this with ferrets infected with influenza virus, H5N1 and H1N1. To understand whether / how convalescent plasma treatment reduces mortality and improve the recovery of patients infected with H5N1 or pandemic H1N1 influenza virus, the FDA plans to study viremia and disease pathogenesis of H5N1 virus and pandemic H1N1 virus infection in the susceptible ferret animal model. To examine blood safety and virus neutralization by convalescent plasma, ferrets will be used to inoculate intranasal with one ml of H5N1 virus with 500 µl to each nare with one times of EID50. Plasma, which will be collected from the ferrets on day0, day30, day60, day120, or day180 post-infection, will be given to ferrets, separately, on day 2 post-infection. Clinical signs of infection, weight, and temperatures are to be recorded daily. Virus load in lung, brain, ileum, nasal turbinate, nasal wash and blood, and cytokines in blood will be tested. To be considered eligible for this study the contractor shall have, at minimum: •Access to a Biosaftey Level 3 (BSL-3) containment laboratory. •Prior documented experience in H5N1 influenza research in ferrets. Interested SMALL BUSINESS ONLY (if available, please include small business representations and certifications and DUNS number) should submit their capability statements no more than 10 pages in length to: Christopher R. McGucken Contract Specialist, Food and Drug Administration Office of Acquisitions and Grant Services 5630 Fishers Lane, Rockville, MD 20851 or Christopher.Mcgucken@fda.hhs.gov Responses to this notice are to be submitted no later than 12pm (noon) EST on May 20th, 2013. Generic capability statements will be considered non-responsive. Capability statements must be tailored to this request and identify the source's capabilities to complete this requirement- including information on availability of a BSL-3 laboratory, and prior experience performing H5N1 research on ferrets.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/FDA-SS-1115918/listing.html)
- Record
- SN03053897-W 20130508/130506235500-dec0e7344620b00ee02cf60d8c605c71 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |